Publications by authors named "Louis Jolivet"

Claim this Profile
D
Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer.
Etienne Auvert, Emmanuel Douez, Louis Jolivet, Tiffany Witkowski, Anne-Catherine Jallas

J Med Chem· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increasing the developability of lambda chain antibodies: engineering to confer protein L binding activity and its consequences.
Bianca Prado-Costa, Gaëlle Dupeyrol, Fanny Boursin, Louis Jolivet, Mariana Fernandes Fonseca

Int J Biol Macromol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metformin-encapsulating immunoliposomes conjugated with anti-TROP 2 antibody fragments for the active targeting of triple-negative breast cancer.
Daiva Vozgirdaite, Emilie Allard-Vannier, Florence Velge-Roussel, Emmanuel Douez, Louis Jolivet

Nanoscale· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Branched pegylated linker-auristatin to control hydrophobicity for the production of homogeneous minibody-drug conjugate against HER2-positive breast cancer.
Emmanuel Douez, Emilie Allard-Vannier, Imène Ait Mohamed Amar, Louis Jolivet, Fanny Boursin

J Control Release· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intra-Domain Cysteines (IDC), a New Strategy for the Development of Original Antibody Fragment-Drug Conjugates (FDCs).
Louis Jolivet, Imène Ait Mohamed Amar, Catherine Horiot, Fanny Boursin, Cyril Colas

Pharmaceutics· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis